Published in Cancer on May 01, 2001
Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg (2007) 1.05
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med (2012) 0.92
The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol (2009) 0.89
Molecular imaging of neuroendocrine tumors. Semin Oncol (2010) 0.89
Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery. Clin Endocrinol (Oxf) (2007) 0.82
Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma. Br J Cancer (2016) 0.80
The dichloromethane fraction of Stemona tuberosa Lour inhibits tumor cell growth and induces apoptosis of human medullary thyroid carcinoma cells. Biologics (2007) 0.77
Cabozantinib for progressive metastatic medullary thyroid cancer: a review. Ther Clin Risk Manag (2014) 0.75
Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis. Hippokratia (2013) 0.75
An introduction to managing medullary thyroid cancer. Hered Cancer Clin Pract (2006) 0.75
Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines. Mol Oncol (2017) 0.75
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer (2003) 2.26
Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet (1999) 1.98
Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab (1993) 1.80
Deoxyhypusine hydroxylase from rat testis. Partial purification and characterization. J Biol Chem (1986) 1.44
Bone loss determined by quantitative ultrasonometry correlates inversely with disease activity in patients with endogenous glucocorticoid excess due to adrenal mass. Eur J Endocrinol (2001) 1.44
The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids (2004) 1.44
High prevalence of thyroid autoantibodies in newly diagnosed rheumatoid arthritis patients. Clin Exp Rheumatol (2003) 1.43
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis (2012) 1.40
In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function. Minerva Cardioangiol (2011) 1.39
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia (2011) 1.38
The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis. Amino Acids (2001) 1.26
Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer (2003) 1.21
Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug Targets (2005) 1.21
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis (2011) 1.18
Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab (2006) 1.17
The heart: an end-organ of GH action. Eur J Endocrinol (2004) 1.16
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis (2011) 1.14
Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ (1999) 1.13
Percutaneous aspiration biopsy of the pancreas under ultrasonic guidance. N Engl J Med (1975) 1.12
Antitumor therapeutic strategies based on the targeting of epidermal growth factor-induced survival pathways. Curr Drug Targets (2005) 1.10
Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr Cancer Drug Targets (2009) 1.10
Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells. Cell Prolif (2012) 1.09
eIF5A isoforms and cancer: two brothers for two functions? Amino Acids (2011) 1.09
The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem (2003) 1.09
WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors. Oncol Rep (2010) 1.09
Acetylation of proteins as novel target for antitumor therapy: review article. Amino Acids (2004) 1.08
BRAF and PIK3CA genes are somatically mutated in hepatocellular carcinoma among patients from South Italy. Cell Death Dis (2012) 1.05
Percutaneous ethanol injection efficacy in the treatment of large symptomatic thyroid cystic nodules: ten-year follow-up of a large series. Thyroid (2002) 1.04
Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications. Curr Drug Targets (2005) 1.03
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia (2000) 1.02
C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ (2007) 1.01
Increased intima-media thickness of the carotid artery wall, normal blood pressure profile and normal left ventricular mass in subjects with primary hyperparathyroidism. Eur J Endocrinol (2002) 1.00
Homology modelling of the human eukaryotic initiation factor 5A (eIF-5A). Protein Eng (2001) 0.97
Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol (1990) 0.97
Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer (2011) 0.97
Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets (2012) 0.97
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm (2010) 0.97
Deregulation of HOX B13 expression in urinary bladder cancer progression. Curr Med Chem (2013) 0.96
Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis (2013) 0.95
Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth. FEBS Lett (1987) 0.94
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br J Cancer (2001) 0.94
Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer (2000) 0.94
FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. J Immunol (1991) 0.93
Interferon alpha2 recombinant and epidermal growth factor modulate proliferation and hypusine synthesis in human epidermoid cancer KB cells. Biochem J (1997) 0.93
Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab (2000) 0.93
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med (2012) 0.92
Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation. Cancer Invest (1989) 0.91
Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol (1992) 0.91
Nanotech revolution for the anti-cancer drug delivery through blood-brain barrier. Curr Cancer Drug Targets (2012) 0.91
Characterization of the anti-inflammatory effect of FK-506 on human mast cells. J Immunol (1991) 0.90
Ret-mediated mitogenesis requires Src kinase activity. Cancer Res (1999) 0.90
EGF activates an inducible survival response via the RAS-> Erk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ (2003) 0.89
Human synovial mast cells. I. Ultrastructural in situ and in vitro immunologic characterization. Arthritis Rheum (1996) 0.89
Modulation of molecular mechanisms involved in protein synthesis machinery as a new tool for the control of cell proliferation. Eur J Biochem (2000) 0.89
A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma. Hum Mutat (1998) 0.89
Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formyl-methionyl-leucyl-phenylalanine. J Allergy Clin Immunol (1996) 0.89
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease. Endocrinology (1998) 0.89
alpha-Interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer (1995) 0.89
Inverse association between free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension (2001) 0.88
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer (2012) 0.88
Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets (2009) 0.87